Tyler Dunlap, a 27-year-old newlywed in San Francisco, is just one of the many American men eagerly awaiting the results of a large clinical trial in India. The trial is studying a new male contraceptive, RISUG (Reversible Inhibition of Sperm Under Guidance): a reversible, nonhormonal contraceptive that provides 10 or more years of protection after a 10-15 minute procedure. Researchers received approval this week to begin enrolling additional study volunteers, after a delay of nearly four years.
